Last reviewed · How we verify
NCT02967536: INcOSA
Investigating the Neuropathology of Obstructive Sleep Apnoea
trial in Obstructive Sleep Apnoea in 27 participants. Completed in 9 September 2019.
9 September 2019
Quick facts
| Lead sponsor | King's College London |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 1 November 2017 |
| Primary completion | 9 September 2019 |
| Estimated completion | 9 September 2019 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Obstructive Sleep Apnoea — all drugs for Obstructive Sleep Apnoea →
- Inflammation — all drugs for Inflammation →
Sponsor
King's College London
Who can join
Adults 18 to 70, male only, with Obstructive Sleep Apnoea or Inflammation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our multi-disciplinary research group works closely with people who have obstructive sleep apnoea. This is a life-long illness that causes breathing to stop during sleep, which leads to low-oxygen in the blood. Breathing restarts when the airway at the back of the throat reopens, usually during arousal from sleep. In some people the repeated arousals from sleep cause daytime sleepiness. Our research has shown that the low blood oxygen levels affect thinking and feeling, and in some cases we think it damages the brain cells involved with memory, attention, emotions and decision-making. This study will investigate the relationship between the amount of oxygen in the blood and the loss (if any) of brain cells. Also how the ability to perform complex tasks is affected in patients that suffer from sleep apnoea. The results will show whether the brain damage in patients with sleep apnoea can be reversed with treatment. These findings will guide doctors in the treatment for sleep apnoea and they will cast light onto the process of memory decline with the aim to preserve brain function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Distinct cognitive changes in male patients with obstructive sleep apnoea without co-morbidities.
Gnoni V, Mesquita M, O'Regan D, Delogu A, et al · · 2023 · cited 14× · PMID 38213473 · DOI 10.3389/frsle.2023.1097946
Verify or expand the search:
- PubMed search for NCT02967536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other King's College London trials
Trials by the same sponsor.
- NCT07357064 — Professional Decision Making in Childbirth. · not yet recruiting
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07228962 — Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies · not yet recruiting
- NCT07365722 — Comparison of Two Non-surgical Procedure to Manage Gum Disease Around Implants. · NA · not yet recruiting
- NCT07378488 — Dance/Movement Therapy for Functional Neurological Disorder · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02967536 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College London
- Last refreshed: 10 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02967536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing